InnoCan Pharma Corporation reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was USD 0.749 million compared to USD 0.054 million a year ago. Net loss was USD 0.168 million compared to USD 3.62 million a year ago. Basic loss per share from continuing operations was USD 0.001 compared to USD 0.016 a year ago.
For the nine months, sales was USD 1.42 million compared to USD 0.18 million a year ago. Net loss was USD 2.56 million compared to USD 9.48 million a year ago. Basic loss per share from continuing operations was USD 0.011 compared to USD 0.044 a year ago.
InnoCan Pharma Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 28, 2022 at 04:23 pm EST
© S&P Capital IQ - 2022